The U.S. Food and Drug Administration put a clinical hold on a Hepatitis B study being conducted on 12 patients across the country by Arrowhead Pharmaceuticals of California, which has most of its operations in Madison.
The company is studying ARC-520, a drug candidate for the treatment of Hep B, but according to the Wisconsin State Journal, regulators put a temporary hold on that study because separate tests being conducted on animals using an intravenously delivered Hep B product called EXI resulted in some animal deaths.
